目次

Table of Content

1. Introduction To Antibody Drug Conjugates
1.1 Overview
1.2 Mechanism of Antibody Drug Conjugates

2. Antibody Drug Conjugates As Cancer Targeted Therapy
2.1 Applications of Antibody Drug Conjugates in Cancer
2.2 Advantages of Antibody Drug Conjugates
2.3 Comparison of Antibody Drug Conjugates With Traditional Therapies

3. Generations of Antibody Drug Conjugates
3.1 Antibody Drug Conjugates - Evolution
3.2 Next Generation Antibody Drug Conjugates Prospects

4. Commercially Approved Antibody Drug Conjugates By Brand Name, Company and Indication

5. Global Cancer Antibody Drug Conjugates Clinical Trials Overview
5.1 By Phase
5.2 By Indication
5.3 By Company
5.4 By Patient Segment
5.5 By Country

6. Global Cancer Antibody Drug Conjugates Market Outlook
6.1 Current Market Scenario
6.2 Future Growth Avenues

7. Global Cancer Antibody Drug Conjugates Research and Market Trends by Region
7.1 US
7.2 China
7.3 Europe
7.4 South Korea
7.5 Australia
7.6 UK
7.7 Canada
7.8 Japan
7.9 India
7.10 Latin America

8. Global Cancer Antibody Drug Conjugates Market Trends and Development By Indications
8.1 Lung Cancer
8.2 Breast cancer
8.3 Leukemia
8.4 Ovarian Cancer
8.5 Gastrointestinal Cancer
8.6 Lymphoma
8.7 Urogenital Cancer
8.8 Cervical Cancer
8.9 Head and Neck Cancer
8.10 Brain Cancer
8.11 Prostate cancer
8.12 Pancreatic Cancer
8.13 Skin cancer
8.14 Esophageal cancer

9. Cancer Antibody Drug Conjugates Development Platforms By Company

10. Approved Cancer Antibody Drug Conjugates - Patent, Dosage and Price Analysis
10.1 Mylotarg
10.1.1 Availability and Patent Insight
10.1.2 Pricing and Dosage Insight 10.2 Adcetris
10.2.1 Availability and Patent Insight
10.2.2 Pricing and Dosage Insight 10.3 Kadcyla
10.3.1 Availability and Patent Insight
10.3.2 Pricing and Dosage Insight 10.4 Besponsa
10.4.1 Availability and Patent Insight
10.4.2 Pricing and Dosage Insight 10.5 Lumoxiti (Market Withdrawal In 2023)
10.5.1 Availability and Patent Insight
10.5.2 Pricing and Dosage Insight 10.6 Polivy
10.6.1 Availability and Patent Insight
10.6.2 Pricing and Dosage Insight 10.7 Padcev
10.7.1 Availability and Patent Insight
10.7.2 Pricing and Dosage Insight 10.8 Enhertu
10.8.1 Availability and Patent Insight
10.8.2 Pricing and Dosage Insight
10.9 Trodelvy
10.9.1 Availability and Patent Insight
10.9.2 Pricing and Dosage Insight 10.10 Blenrep (Partial Market Withdrawal In 2023)
10.10.1 Availability and Patent Insight
10.10.2 Pricing and Dosage Insight 10.11 Zynlonta
10.11.1 Availability and Patent Insight
10.11.2 Pricing and Dosage Insight
10.12 Tivdak
10.12.1 Availability and Patent Insight
10.12.2 Pricing and Dosage Insight 10.13 Elahere
10.13.1 Availability and Patent Insight
10.13.2 Pricing and Dosage Insight
10.14 Ujvira
10.14.1 Availability and Patent Insight
10.14.2 Pricing and Dosage Insight 10.15 Akalux
10.15.1 Availability and Patent Insight
10.15.2 Pricing and Dosage Insight
10.16 Aidixi
10.16.1 Availability Insight

11. Approved Cancer Antibody Drug Conjugates - Sales Insights and Forecast 2028
11.1 Adcetris
11.2 Padcev
11.3 Tivdak
11.4 Polivy
11.5 Kadcyla
11.6 Besponsa
11.7 Enhertu
11.8 Trodelvy
11.9 Zynlonta
11.10 Elahere
11.11 Blenrep

12. Global Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase
12.1 Research
12.2 Preclinical
12.3 Phase I
12.4 Phase I/II
12.5 Phase II
12.6 Phase II/III
12.7 Phase III
12.8 Preregistration

13. Marketed Cancer Antibody Drug Conjugates Clinical Insight By Company, Country and Indication

14. Cancer Antibody Drug Conjugates Combination Therapies

15. Global Cancer Antibody Drug Conjugates Market Overview
15.1 Key Market Growth Drivers
15.2 Challenges For Market Growth

16. Competitive Landscape
16.1 Biocytogen
16.2 Bristol Myers Squibb
16.3 Eli Lilly
16.4 Innovent Biologics
16.5 Merck
16.6 Pfizer
16.7 Affinity Biopharma
16.8 Biokin
16.9 Synaffix
16.10 ADC Therapeutics
16.11 AstraZeneca
16.12 Daiichi Sankyo
16.13 Duality Biologics
16.14 Immunogen
16.15 LigaChem Biosciences

List of Figures & Tables
Figure 1-1: Antibody Drug Conjugates - General Working Mechanism
Figure 2-1: Advantages of Antibody Drug Conjugates
Figure 3-1: Antibody-Drug Conjugates - Approval by Generation
Figure 3-2: Cancer Antibody Drug Conjugates - Opportunities for Next-Generation Development
Figure 5-1: Global - Cancer Antibody Drug Conjugates In Clinical Trials By Phase, 2024 Till 2030
Figure 5-2: Global- Cancer Antibody Drug Conjugates In Clinical Trials By Indication, 2024 Till 2030
Figure 5-3: Global - Cancer Antibody Drug Conjugates In Clinical Trials By Company, 2024 Till 2030
Figure 5-4: Global - Cancer Antibody Drug Conjugates In Clinical Trials By Patient Segment, 2024 Till 2030
Figure 5-5: Global - Cancer Antibody Drug Conjugates In Clinical Pipeline By Country, 2024 Till 2030
Figure 6-1: Global - Cancer Antibody Drug Conjugates Market (US$ Million), 2020-2024
Figure 6-2: Global -Cancer Antibody Drug Conjugates Sales by Drug (US$ Million), Q1’2024
Figure 6-3: Global - Cancer Antibody Drug Conjugates Sales by Drug (US$ Million), Q2’2024
Figure 6-4: Global - Cancer Antibody Drug Conjugates Sales by Drug (US$ Million), H1’2024
Figure 6-5: Global - Cancer Antibody Drug Conjugates Market Share by Drugs (%), H1’2024
Figure 6-6: Global - Cancer Antibody Drug Conjugates Market (US$ Million), Q1 and Q2’2024
Figure 6-7: Global - Cancer Antibody Drug Conjugates Market by Drug (US$ Million), 2023
Figure 6-8: Global - Cancer Antibody Drug Conjugates Market Share by Drugs (%), 2023
Figure 6-9: Global - Cancer Antibody Drug Conjugates Market (US$ Million), Q1-Q4’2023
Figure 6-10: Global - Cancer Antibody Drug Conjugates Market Forecast (US$ Billion), 2024 - 2030
Figure 7-1: Daiichi Sankyo DXd ADC Technology - Clinical Candidates
Figure 7-2: India - Branded v/s Biosimilar Trastuzumab Emtansine Price by Supply (US$), October’2024
Figure 8-1: Datopotamab Deruxtecan Phase 3 (NCT04656652) Study - Initiation and Completion Year
Figure 8-2: Luveltamab tazevibulin Phase 2 (NCT06555263) Study - Initiation and Completion Year
Figure 8-3: Ifinatamab Deruxtecan Phase 3 (NCT06203210) Study - Initiation and Completion Year
Figure 8-4: Sigvotatug Vedotin Phase 3 (NCT06012435) Study - Initiation and Completion Year
Figure 8-5: Sacituzumab Tirumotecan Phase 3 (NCT06074588) Study - Initiation and Completion Year
Figure 8-6: Datopotamab deruxtecan Phase 3 (NCT05104866) Study - Initiation and Completion Year
Figure 8-7: Datopotamab deruxtecan Phase 3 (NCT06112379) Study - Initiation and Completion Year
Figure 8-8: TQB2102 Phase 3 (NCT06561607) Study - Initiation and Completion Year
Figure 8-9: ORM-5029 Phase 1 (NCT05511844) Study - Initiation and Completion Year
Figure 8-10: BMS-986497 Phase 1 (NCT06419634) Study - Initiation and Completion Year
Figure 8-11: JBH492 Phase 1 (NCT04240704) Study - Initiation and Completion Year
Figure 8-12: Rinatabart sesutecan Phase 3 (NCT06619236) Study - Initiation and Completion Year
Figure 8-13: Luveltamab tazevibulin Phase 2/3 (NCT05870748) Study - Initiation and Completion Year
Figure 8-14: Raludotatug Deruxtecan (R-DXd) Phase 2/3 (NCT06161025) Study - Initiation and Completion Year
Figure 8-15: AZD5335 Phase 1/2 (NCT05797168) Study - Initiation and Completion Year
Figure 8-16: Dato-DXd Phase 2 (NCT05489211) Study - Initiation and Completion Year
Figure 8-17: IKS014 Phase 1 (NCT05872295) Study - Initiation and Completion Year
Figure 8-18: AZD0901 Phase 2 (NCT06219941) Study - Initiation and Completion Year
Figure 8-19: Polatuzumab Vedotin Phase 2 (NCT05410418) Study - Initiation and Completion Year
Figure 8-20: Loncastuximab tesirine Phase 2 (NCT05453396) Study - Initiation and Completion Year
Figure 8-21: Blenrep Phase 2 (NCT04676360) Study - Initiation and Completion Year
Figure 8-22: Zilovertamab vedotin Phase 1/2 (NCT06395103) Study - Initiation and Completion Year
Figure 8-23: Padcev Phase 2 (NCT05775471) Study - Initiation and Completion Year
Figure 8-24: Trodelvy Phase 2 (NCT05581589) Study - Initiation and Completion Year
Figure 8-25: BL-B01D1 Phase 2 (NCT05785039) Study - Initiation and Completion Year
Figure 8-26: 9MW2821 Phase 3 (NCT06196736) Study - Initiation and Completion Year
Figure 8-27: Trodelvy Phase 2 (NCT05838521) Study - Initiation and Completion Year
Figure 8-28: Enhertu Phase 2 (NCT04482309) Study - Initiation and Completion Year
Figure 8-29: 9MW2821 Phase 1/2 (NCT05216965) Study - Initiation and Completion Year
Figure 8-30: Aidixi Phase 2 (NCT06003231) Study - Initiation and Completion Year
Figure 8-31: Padcev Phase 2 (NCT04225117) Study - Initiation and Completion Year
Figure 8-32: Ozuriftamab vedotin Phase 1/2 (NCT03504488) Study - Initiation and Completion Year
Figure 8-33: Panitumumab-IRDye800 Phase 1/2 (NCT03510208) Study - Initiation and Completion Year
Figure 8-34: Patritumab deruxtecan (HER3-DXd) Phase 2 (NCT05865990) Study - Initiation and Completion Year
Figure 8-35: Trodelvy Phase 2 (NCT03725761) Study - Initiation and Completion Year
Figure 8-36: HS-20093 Phase 2 (NCT06001255) Study - Initiation and Completion Year
Figure 8-37: FOR46 Phase 1b/2 (NCT05011188) Study - Initiation and Completion Year
Figure 8-38: ARX517 Phase 1 (NCT04662580) Study - Initiation and Completion Year
Figure 8-39: Pancreatic Ductal Adenocarcinoma - Prevalence Compared to Other Pancreatic Cancer Types
Figure 8-40: SOT102 Phase 1/2 (NCT05525286) Study - Initiation and Completion Year
Figure 8-41: TORL-2-307 Phase 1 (NCT05156866) Study - Initiation and Completion Year
Figure 8-42: EBC-129 Phase 1 (NCT05701527) Study - Initiation and Completion Year
Figure 8-43: Panitumumab-IRDye800 Phase 1/2 (NCT03384238) Study - Initiation and Completion Year
Figure 8-44: Ozuriftamab vedotin Phase 1/2 (NCT03504488) Study - Initiation and Completion Year
Figure 8-45: Vobramitamab duocarmazine (MGC018) Phase 1 (NCT05293496) Study - Initiation and Completion Year
Figure 8-46: AMT253 Phase 1/2 (NCT06209580) Study - Initiation and Completion Year
Figure 8-47: Zirconium Zr 89 Crefmirlimab Berdoxam Phase 2 (NCT05013099) Study - Initiation and Completion Year
Figure 8-48: Enhertu Phase 2 (NCT05480384) Study - Initiation and Completion Year
Figure 8-49: HS-20093 Phase 2 (NCT06112704) Study - Initiation and Completion Year
Figure 8-50: DP303c Phase 1/2 (NCT06577376) Study - Initiation and Completion Year
Figure 9-1: Proprietary ADC Technology - Seagen
Figure 9-2: ALE.P02 and ALE.P03 - Alentis Therapeutics
Figure 9-3: TRAAC- Tallac Therapeutics
Figure 9-4: ATAC- Heidelberg Pharma
Figure 9-5: Tub-tagandreg; and P5 - Tubulis
Figure 10-1: Mylotarg - FDA Approval, Withdrawal and Re-Approval Year
Figure 10-2: Mylotarg - Approval Year by Region
Figure 10-3: Mylotarg - Cost of 4.5 mg Supply in US (US$), October’2024
Figure 10-4: Mylotarg - Cost of 5 mg Supply in UK (US$), October’2024
Figure 10-5: US - Adcetris FDA Approval Year by Indication
Figure 10-6: Adcetris - Approval Year by Region
Figure 10-7: Japan - Adcetris PMDA Approval Year by Indication
Figure 10-8: US - Adcetris Orphan Drug Designation Approval Year by Indication
Figure 10-9: Adcetris - Patent Expiration by Region
Figure 10-10: Adcetris - Cost of 50 mg Supply in US and UK (US$), October’2024
Figure 10-11: US - Kadcyla FDA Approval Year by Indication
Figure 10-12: Kadcyla - Approval Year by Region
Figure 10-13: US - Kadcyla FDA Approval and Patent Expiration Year
Figure 10-14: Kadcyla - Cost of Supply in US, Europe and UK (US$), October’2024
Figure 10-15: Kadcyla - Recommended Dose after 1st and 2nd Dose Reduction (mg/kg)
Figure 10-16: Besponsa - Approval Year by Region
Figure 10-17: Besponsa - Cost of 0.9 mg Supply in US, October’2024
Figure 10-18: Besponsa - Cost of 1 mg Supply in Europe and UK (US$), October’2024
Figure 10-19: Lumoxiti - Orphan Designation Years
Figure 10-20: Lumoxiti - Patent Expiry Years
Figure 10-21: Lumoxiti - Cost of 1 mg Supply in US and Europe (US$), October’2024
Figure 10-22: Polivy - Approval Year by Region
Figure 10-23: Polivy - Orphan Drug Designation Approval Year by Region
Figure 10-24: US - Polivy Orphan Drug Designation Approval and Exclusivity Year
Figure 10-25: Polivy - Cost of 140 mg Supply in Europe (US$), October’2024
Figure 10-26: Polivy - Cost of 30 and 140 mg Supply in US and UK (US$), October’2024
Figure 10-27: Padcev - Approval Year by Region
Figure 10-28: US - Padcev FDA Approval and Patent Expiration Year
Figure 10-29: Padcev - Cost of 20 and 30 mg Supply In US and Europe (US$), October’2024
Figure 10-30: Enhertu - Approval Year by Region
Figure 10-31: US - Polivy FDA Approval Year by Indication
Figure 10-32: Enhertu - FDA Orphan Drug Designation and Exclusivity Expiration Year
Figure 10-33: Enhertu - Cost of 100 mg Supply In US, Europe and UK (US$), October’2024
Figure 10-34: US - Trodelvy FDA Approval by Indication
Figure 10-35: Trodelvy - Approval Year by Region
Figure 10-36: Trodelvy - Patent Expiration by Region
Figure 10-37: Trodelvy - Cost of 180 mg Supply In US and UK (US$), October’2024
Figure 10-38: Trodelvy - Cost of 180 and 200 mg Supply In Europe (US$), October’2024
Figure 10-39: Blenrep - FDA and EMA Orphan Drug Designations
Figure 10-40: Blenrep - FDA and EMA Approval
Figure 10-41: Zynlonta - FDA and EMA Approval Years
Figure 10-42: Zynlonta - FDA and EMA Orphan Drug Designation Years
Figure 10-43: Zynlonta - Cost of 10 mg Supply In US, Europe and UK (US$), October’2024
Figure 10-44: Tivdak - Cost of 40 mg Supply In US and Europe (US$), October’2024
Figure 10-45: Elahere - Cost of Unit and Supply In US (US$), October’2024
Figure 10-46: Ujvira - Cost of 100 mg and 160 mg Supply (US$), October’2024
Figure 10-47: Akalux - Sakigake Designation and PMDA Approval Year
Figure 10-48: Aidixi - China Approval Year and FDA Breakthrough Therapy Designation Year
Figure 11-1: Adcetris - Global Annual Sales (US$ Million), 2020-2024
Figure 11-2: Adcetris - Global Quarterly Sales (US$ Million), Q1 and Q2’2024
Figure 11-3: Adcetris - Global Quarterly Sales (US$ Million), Q1-Q4’2023
Figure 11-4: Padcev - Global Annual Sales (US$ Million), 2020-2024
Figure 11-5: Padcev - Global Quarterly Sales (US$ Million), Q1 and Q2’2024
Figure 11-6: Padcev - Global Quarterly Sales (US$ Million), Q1-Q4’2023
Figure 11-7: Tivdak - Global Annual Sales (US$ Million), 2021-2024
Figure 11-8: Tivdak - Global Quarterly Sales (US$ Million), Q1 and Q2’2024
Figure 11-9: Tivdak - Global Quarterly Sales (US$ Million), Q1-Q4’2023
Figure 11-10: Polivy - Global Sales Values (US$ Million), 2020-2024
Figure 11-11: Polivy - Global Quarterly Sales Values (US$ Million), Q1 and Q2’2024
Figure 11-12: Polivy - Global Sales By Region (%), H1’2024
Figure 11-13: Polivy - US Annual Sales Values (US$ Million), 2020-2024
Figure 11-14: Polivy - US Quarterly Sales Values (US$ Million), Q1 and Q2’2024
Figure 11-15: Polivy - Europe Annual Sales Values (US$ Million), 2020-2024
Figure 11-16: Polivy - Europe Quarterly Sales Values (US$ Million), Q1 and Q2’2024
Figure 11-17: Polivy - Japan Annual Sales Values (US$ Million), 2020-2024
Figure 11-18: Polivy - Global Sales By Region (US$ Million), Q1-Q4’2023
Figure 11-19: Polivy - Global Sales By Region (%), 2023
Figure 11-20: Polivy - Global Quarterly Sales Values (US$ Million), Q1-Q4’2023
Figure 11-21: Polivy - US Quarterly Sales Values (US$ Million), Q1-Q4’2023
Figure 11-22: Polivy - Europe Quarterly Sales Values (US$ Million), Q1-Q4’2023
Figure 11-23: Polivy - Japan Quarterly Sales Values (US$ Million), Q1-Q4’2023
Figure 11-24: Polivy - ROW Quarterly Sales Values (US$ Million), Q1-Q4’2023
Figure 11-25: Kadcyla - Global Sales Values (US$ Million), 2020-2024
Figure 11-26: Kadcyla - Global Quarterly Sales Values (US$ Million), Q1 and Q2’2024
Figure 11-27: Kadcyla - Global Sales By Region (%), H1’2024
Figure 11-28: Kadcyla - Global Quarterly Sales Values (US$ Million), Q1-Q4’2023
Figure 11-29: Kadcyla - Global Sales By Region (US$ Million), Q1-Q4’2023
Figure 11-30: Kadcyla - Global Sales By Region (%), 2023
Figure 11-31: Kadcyla - US Annual Sales Values (US$ Million), 2020-2024
Figure 11-32: Kadcyla - US Quarterly Sales Values (US$ Million), Q1 and Q2’2024
Figure 11-33: Kadcyla - US Quarterly Sales Values (US$ Million), Q1-Q4’2023
Figure 11-34: Kadcyla - Europe Annual Sales Values (US$ Million), 2020-2024
Figure 11-35: Kadcyla - Europe Quarterly Sales Values (US$ Million), Q1 and Q2’2024
Figure 11-36: Kadcyla - Europe Quarterly Sales Values (US$ Million), Q1-Q4’2023
Figure 11-37: Kadcyla - Japan Annual Sales Values (US$ Million), 2020-2024
Figure 11-38: Kadcyla - Japan Quarterly Sales Values (US$ Million), Q1 and Q2’2024
Figure 11-39: Kadcyla - Japan Quarterly Sales Values (US$ Million), Q1-Q4’2023
Figure 11-40: Kadcyla - ROW Annual Sales Values (US$ Million), 2020-2024
Figure 11-41: Kadcyla - ROW Quarterly Sales Values (US$ Million), Q1 and Q2’2024
Figure 11-42: Kadcyla - ROW Quarterly Sales Values (US$ Million), Q1-Q4’2023
Figure 11-43: Besponsa - Global Annual Sales (US$ Million), 2020-2023
Figure 11-44: Besponsa - Global Sales by Region (US$ Million), 2023
Figure 11-45: Besponsa - Quarterly Sales by Region (%), 2023
Figure 11-46: Besponsa - Global Quarterly Sales (US$ Million), Q1-Q4’2023
Figure 11-47: Besponsa - US Annual Sales (US$ Million), 2020-2023
Figure 11-48: Besponsa - Europe Quarterly Sales (US$ Million), 2022
Figure 11-49: Besponsa - ROW Quarterly Sales (US$ Million), 2022
Figure 11-50: Enhertu - Global Annual Sales (US$ Million), 2020-2024
Figure 11-51: Enhertu - Global Quarterly Sales Values (US$ Million), Q1 and Q2’2024
Figure 11-52: Enhertu - Global Quarterly Sales (US$ Million), 2022
Figure 11-53: Trodelvy - Global Annual Sales (US$ Million), 2020-2024
Figure 11-54: Trodelvy - Global Quarterly Sales (US$ Million), Q1 and Q2’2024
Figure 11-55: Trodelvy - Global Quarterly Sales (US$ Million), Q1-Q4’2023
Figure 11-56: Trodelvy - Annual Sales By Region (US$ Million), 2023
Figure 11-57: Trodelvy - Annual Sales By Region (%), 2023
Figure 11-58: Trodelvy - US Annual Sales (US$ Million), 2020-2024
Figure 11-59: Trodelvy - US Quarterly Sales (US$ Million), Q1 and Q2’2024
Figure 11-60: Trodelvy - US Quarterly Sales (US$ Million), Q1-Q4’2023
Figure 11-61: Trodelvy - Europe Annual Sales (US$ Million), 2020-2024
Figure 11-62: Trodelvy - Europe Quarterly Sales (US$ Million), Q1 and Q2’2024
Figure 11-63: Trodelvy - Europe Quarterly Sales (US$ Million), Q1-Q4’2023
Figure 11-64: Trodelvy - ROW Annual Sales (US$ Million), 2020-2024
Figure 11-65: Trodelvy - ROW Quarterly Sales (US$ Million), Q1 and Q2’2024
Figure 11-66: Trodelvy - ROW Quarterly Sales (US$ Million), Q1-Q4’2023
Figure 11-67: Zynlonta - Global Annual Sales (US$ Million), 2021-2024
Figure 11-68: Zynlonta - Global Quarterly Sales (US$ Million), Q1 and Q2’2024
Figure 11-69: Zynlonta - Global Quarterly Sales (US$ Million), Q1-Q4’2023
Figure 11-70: Elahere - Global Annual Sales (US$ Million), 2022-2024
Figure 11-71: Elahere - Global Quarterly Sales (US$ Million), Q1 and Q2’2024
Figure 11-72: Elahere - Global Quarterly Sales (US$ Million), Q1-Q4’2023
Figure 11-73: Blenrep - Global Annual Sales (US$ Million), 2020-2023
Figure 11-74: Blenrep - Europe Quarterly Sales Value (US$ Million), Q1-Q4’2023
Figure 14-1: Antibody Drug Conjugate Combinations in Studies
Figure 14-2: Approved Antibody Drug Conjugate Combinations

List of Tables
Table 3-1: First Generation Antibody Drug Conjugates - Examples
Table 3-2: Second Generation Antibody Drug Conjugates - Examples
Table 3-3: Third Generation Antibody Drug Conjugates - Examples
Table 3-4: Fourth Generation Antibody Drug Conjugates - Examples
Table 4-1: Approved Antibody Drug Conjugates
Table 6-1: Cancer Antibody Drug Conjugates Market - Recent Acquisition Deals
Table 6-2: Cancer Antibody Drug Conjugates - Recent Collaborations
Table 6-3: Cancer Antibody Drug Conjugates - Companies Securing Funding for Clinical Development
Table 6-4: Cancer Antibody Drug Conjugates - Companies Announcing Plans for Manufacturing Facilities
Table 6-5: Cancer Antibody Drug Conjugates - Recent Regulatory Designations
Table 6-6: Cancer Antibody Drug Conjugates - Recent IND Clearances
Table 7-1: US - Approved Cancer Antibody Drug Conjugates, October’2024
Table 7-2: US - Antibody Drug Conjugate Under FDA Review, October’2024
Table 7-3: China - Approved Antibody Drug Conjugates, October’2024
Table 7-4: EU - Approved Cancer Antibody Drug Conjugates, October’2024
Table 7-5: Australia - Approved Cancer Antibody Drug Conjugates, October’2024
Table 7-6: Canada - Approved Cancer Antibody Drug Conjugates, October’2024
Table 7-7: Japan - Approved Cancer Antibody Drug Conjugates, October’2024
Table 8-1: Lung Cancer - Approved Antibody Drug Conjugates
Table 8-2: Breast Cancer - Approved Antibody Drug Conjugates
Table 8-3: Leukemia - Approved Antibody Drug Conjugates
Table 8-4: Ovarian Cancer - Approved Antibody Drug Conjugate
Table 8-5: Gastrointestinal Cancer - Approved Antibody Drug Conjugates
Table 8-6: Lymphoma - Approved Antibody Drug Conjugates
Table 8-7: Urogenital Cancer - Approved Antibody Drug Conjugates
Table 8-8: Cervical Cancer - Approved Antibody Drug Conjugates
Table 8-9: Head and Neck Cancer - Approved Antibody Drug Conjugates
Table 10-1: Adcetris - Recommended Dosage
Table 14-1: Antibody Drug Conjugate Combinations - Ongoing Clinical Trials